New Cholesterol Pill Cuts Bad Cholesterol 60% in Trials

More than 86 million Americans have dangerously high cholesterol, but fewer than half are getting treated for a condition that silently raises their risk of heart attack and stroke every single day.

That could soon change. The FDA just approved Lipfendra, a daily pill that slashed bad cholesterol levels by 50% to 60% in clinical trials. The results are so promising that Spokane cardiologist Dr. Adam Noyes plans to prescribe it to about 80% of his high cholesterol patients.

"This is my bread and butter for the patients I see in my office," said Noyes, who works at MultiCare Pulse Heart Institute. He believes the drug will have "a huge impact on cholesterol management."

High cholesterol causes yellow plaque to build up inside arteries over decades. Without treatment, this buildup is a ticking time bomb. If the plaque cracks, it triggers instant blood clotting that can cause sudden cardiac death with no warning.

"It really is the most heartbreaking. Because there is no warning, and it is so hard to know when there could be a crack in the plaque," said Dr. Norman Lepor, director of the National Heart Institute.

Most people think diet and exercise cause high cholesterol, but genetics are actually the main culprit. Lifestyle changes help, but they're usually not enough on their own.

Statins have been the go-to medication for years, reducing cholesterol production by about 50% for many patients. Lipfendra attacks the problem from a completely different angle. While statins prevent new cholesterol from forming, Lipfendra helps the liver remove cholesterol that's already circulating in the blood.

The drug blocks an enzyme called PCSK9 that normally interferes with the liver's ability to clear out bad cholesterol. By stopping this interference, the body can naturally break down dangerous cholesterol more effectively.

The Ripple Effect

An injectable version of Lipfendra has existed for 10 years, but frequent shots at home proved difficult and expensive at $500 to $600 monthly. The new daily pill costs $315 per month out of pocket and will be available within weeks.

Lepor led the 24-week clinical trial that earned FDA approval. Patients taking Lipfendra with statins saw their cholesterol drop by 60% on average. Side effects like dizziness and diarrhea occurred at the same rate as the placebo group.

The switch from injections to a simple daily pill is what makes this a "game changer," according to Noyes. Doctors can now easily prescribe and monitor the treatment, making it accessible to millions more patients.

For the 43 million Americans with untreated high cholesterol, this breakthrough offers a realistic path to protection from heart attacks and strokes that strike without warning.